
==== Front
NPJ Aging
NPJ Aging
NPJ Aging
2731-6068
Nature Publishing Group UK London

39251602
164
10.1038/s41514-024-00164-2
Article
Glucose metabolism and smaller hippocampal volume in elderly people with normal cognitive function
Shima Ayano 1
Noguchi-Shinohara Moeko m-nohara@med.kanazawa-u.ac.jp

1
Shibata Shutaro 1
Usui Yuta 1
Tatewaki Yasuko 2
Thyreau Benjamin 3
Hata Jun 456
Ohara Tomoyuki 47
http://orcid.org/0000-0002-1011-9879
Honda Takanori 4
Taki Yasuyuki 2
Nakaji Shigeyuki 8
http://orcid.org/0000-0002-6207-8343
Maeda Tetsuya 9
Mimura Masaru 10
Nakashima Kenji 11
http://orcid.org/0000-0003-4409-3096
Iga Jun-ichi 12
Takebayashi Minoru 13
Nishijo Hisao 14
Ninomiya Toshiharu 45
http://orcid.org/0000-0001-8454-6155
Ono Kenjiro onoken@med.kanazawa-u.ac.jp

1
the Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD) study groupNinomiya Toshiharu 15
Hata Jun 15
Shibata Mao 15
Honda Takanori 15
Ohara Tomoyuki 16
Akiyama Masato 17
Nakaji Shigeyuki 18
Murashita Koichi 18
Mikami Tatsuya 18
Jung Songee 18
Misawa Mina 18
Maeda Tetsuya 19
Ishizuka Naoki 19
Akasaka Hiroshi 19
Terayama Yasuo 20
Yonezawa Hisashi 21
Takahashi Junko 22
Ono Kenjiro 23
Noguchi-Shinohara Moeko 23
Iwasa Kazuo 23
Yuki-Nozaki Sohshi 23
Yamada Masahito 24
Mimura Masaru 25
Bun Shogyoku 25
Niimura Hidehito 25
Shikimoto Ryo 25
Kida Hisashi 25
Nakashima Kenji 26
Fukada Yasuyo 26
Kowa Hisanori 26
Nakano Toshiya 26
Wada Kenji 27
Kishi Masafumi 28
Ozaki Tomoki 29
Tachibana Ayumi 29
Yoshino Yuta 29
Iga Jun-ichi 29
Ueno Shu-ichi 29
Takebayashi Minoru 30
Ishikawa Tomohisa 30
Yuki Seiji 30
Fukuhara Ryuji 30
Koyama Asuka 30
Hashimoto Mamoru 31
Ikeda Manabu 32
Kokubo Yoshihiro 33
Uchida Kazuhiro 34
Esaki Midori 34
Taki Yasuyuki 35
Tatewaki Yasuko 35
Thyreau Benjamin 35
Yonemoto Koji 36
Yoshida Hisako 37
Muto Kaori 38
Inoue Yusuke 38
Ri Izen 38
Momozawa Yukihide 39
Terao Chikashi 39
Kubo Michiaki 40
Kiyohara Yutaka 40

1 https://ror.org/02hwp6a56 grid.9707.9 0000 0001 2308 3329 Department of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
2 https://ror.org/01dq60k83 grid.69566.3a 0000 0001 2248 6943 Department of Aging Research and Geriatric Medicine, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
3 https://ror.org/01dq60k83 grid.69566.3a 0000 0001 2248 6943 Smart Aging Research Center, Tohoku University, Sendai, Japan
4 https://ror.org/00p4k0j84 grid.177174.3 0000 0001 2242 4849 Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
5 https://ror.org/00p4k0j84 grid.177174.3 0000 0001 2242 4849 Center for Cohort Studies, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
6 https://ror.org/00p4k0j84 grid.177174.3 0000 0001 2242 4849 Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
7 https://ror.org/00p4k0j84 grid.177174.3 0000 0001 2242 4849 Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
8 https://ror.org/02syg0q74 grid.257016.7 0000 0001 0673 6172 Department of Social Medicine, Graduate School of Medicine, Hirosaki University, Aomori, Japan
9 https://ror.org/04cybtr86 grid.411790.a 0000 0000 9613 6383 Division of Neurology and Gerontology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Iwate, Japan
10 https://ror.org/02kn6nx58 grid.26091.3c 0000 0004 1936 9959 Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
11 https://ror.org/03ntccx93 grid.416698.4 National Hospital Organization, Matsue Medical Center, Shimane, Japan
12 https://ror.org/017hkng22 grid.255464.4 0000 0001 1011 3808 Department of Neuropsychiatry, Ehime University Graduate School of Medicine, Ehime University, Ehime, Japan
13 https://ror.org/02cgss904 grid.274841.c 0000 0001 0660 6749 Faculty of Life Sciences, Department of Neuropsychiatry, Kumamoto University, Kumamoto, Japan
14 https://ror.org/05ptpxn60 grid.413101.6 0000 0004 0480 2692 Faculty of Human Sciences, University of East Asia, Yamaguchi, Japan
15 grid.177174.3 0000 0001 2242 4849 Kyushu University ([Epidemiology and Public Health], Fukuoka, Japan
16 https://ror.org/00p4k0j84 grid.177174.3 0000 0001 2242 4849 Neuropsychiatry, Kyushu University, Fukuoka, Japan
17 https://ror.org/00p4k0j84 grid.177174.3 0000 0001 2242 4849 Ocular Pathology and Imaging Science, Kyushu University, Fukuoka, Japan
18 https://ror.org/02syg0q74 grid.257016.7 0000 0001 0673 6172 Hirosaki University, Hirosaki, Japan
19 https://ror.org/04cybtr86 grid.411790.a 0000 0000 9613 6383 Iwate Medical University, Morioka, Japan
20 Shonan Keiiku Hospital, Fujisawa, Japan
21 https://ror.org/04prxcf74 grid.459661.9 0000 0004 0377 6496 Japanese Red Cross Morioka Hospital, Morioka, Japan
22 Kitakami Saiseikai Hospital, Kitakami, Japan
23 https://ror.org/02hwp6a56 grid.9707.9 0000 0001 2308 3329 Kanazawa University, Kanazawa, Japan
24 https://ror.org/01yth7f19 grid.415524.3 0000 0004 1764 761X Kudanzaka hospital, Tokyo, Japan
25 https://ror.org/02kn6nx58 grid.26091.3c 0000 0004 1936 9959 Keio University School of Medicine, Minato, Japan
26 Matsue Medical Center, Matsue, Japan
27 https://ror.org/059z11218 grid.415086.e 0000 0001 1014 2000 Kawasaki Medical School, Okayama, Japan
28 Tottori Red Cross Hospital, Tottori, Japan
29 https://ror.org/017hkng22 grid.255464.4 0000 0001 1011 3808 Ehime University, Matsuyama, Japan
30 https://ror.org/02cgss904 grid.274841.c 0000 0001 0660 6749 Kumamoto University, Kumamoto, Japan
31 https://ror.org/05kt9ap64 grid.258622.9 0000 0004 1936 9967 Kindai University Faculty of Medicine, Osaka, Japan
32 https://ror.org/035t8zc32 grid.136593.b 0000 0004 0373 3971 Osaka University Medical School, Osaka, Japan
33 https://ror.org/01v55qb38 grid.410796.d 0000 0004 0378 8307 National Cerebral and Cardiovascular Center, Suita, Japan
34 https://ror.org/00qm2vr07 grid.412000.7 0000 0004 0640 6482 Nakamura-Gakuen University, Fukuoka, Japan
35 https://ror.org/01dq60k83 grid.69566.3a 0000 0001 2248 6943 Tohoku University, Sendai, Japan
36 https://ror.org/02z1n9q24 grid.267625.2 0000 0001 0685 5104 University of the Ryukyu, Nishihara, Japan
37 https://ror.org/01hvx5h04 Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
38 https://ror.org/057zh3y96 grid.26999.3d 0000 0001 2169 1048 University of Tokyo, Bunkyo City, Japan
39 https://ror.org/04mb6s476 grid.509459.4 0000 0004 0472 0267 RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
40 https://ror.org/03y740t04 grid.482571.d Hisayama Research Institute for Lifestyle Diseases, Fukuoka, Japan
9 9 2024
9 9 2024
12 2024
10 1 3918 10 2023
6 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
We investigated associations of glycemic measures, and insulin resistance and secretion measures with hippocampal and subfield volumes. In this cross-sectional study, 7400 community-dwelling participants underwent brain MRI and health checkups between 2016 and 2018. Hemoglobin A1c (HbA1c), glycated albumin (GA), homeostasis model assessment for insulin resistance (HOMA-IR), and HOMA of percent β-cell function (HOMA-β) were evaluated. The associations of each measure with a smaller volume of the hippocampus and twelve hippocampal subfields were investigated. As a result, higher HbA1c or GA and lower HOMA-β levels were significantly associated with smaller volumes in multiple hippocampal subfields. Furthermore, even when we analyzed non-diabetic individuals, substantial associations remained between higher GA or lower HOMA-β levels and smaller volumes of the whole hippocampus or the fimbria. Our findings indicate that postprandial glucose fluctuations, postprandial hyperglycemia, and low insulin secretion have a specific effect on the development of smaller hippocampal volume, suggesting that primary prevention of diabetes and/or sufficient glucose control are important for the prevention of dementia.

Subject terms

Risk factors
Dementia
https://doi.org/10.13039/100009619 Japan Agency for Medical Research and Development (AMED) JP22dk0207053 Ono Kenjiro Suntory Holdings Limited (Osaka, Japan)issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Alzheimer’s disease (AD) and cognitive impairments are costly medical problems worldwide, and diabetes mellitus (DM) is a major risk factor for AD and cognitive impairments1–8. It has been reported that patients with type 2 DM and animal models with DM have impaired cognitive functions such as memory, particularly episodic and spatial memory, learning, cognitive flexibility, executive function, processing speed, and attention5,6,9.

Several studies have shown considerable associations between type 2 DM and smaller volume of the hippocampus and its subfields1–4,10–12, and found that abnormalities of some glycemic measures, insulin resistance, and secretion measures were associated with smaller volume of the hippocampus and its subfields2,10–12. Hyperglycemia, impaired insulin secretion, and insulin resistance have been considered to impair the hippocampus to cause oxidative stress13,14, inflammation, and vascular damage11, decreased neurogenesis2,12 and excessive production of amyloid-β (Aβ)11, and phosphorylation of tau11. However, there were inconsistent findings on which subfields had been smaller in patients with DM or abnormalities of glycemic or insulin resistance/secretion measures. There have been no reports of simultaneous studies of glycemic measures, insulin resistance, and secretion in the same participant group, and few papers have excluded patients with dementia and mild cognitive impairment. Large-scale studies examining the associations between glucose metabolism markers and the hippocampus in people without dementia are essential to understanding these relationships.

The Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD) is an ongoing community-based observational study for dementia in eight research sites in Japan, in which ~10,000 older participants have undergone a brain MRI examination and the following glycemic measures at the baseline survey15. Hemoglobin A1c (HbA1c) is a commonly used glycemic measure in clinical fields, and glycated albumin (GA) is an alternative glycemic measure of postprandial glucose fluctuations16. Because the glycation speed of albumin is faster than that of hemoglobin17, therefore, the GA levels rise faster than the HbA1c levels in response to the rapid increase in blood glucose levels16. Furthermore, the homeostasis model assessment for insulin resistance (HOMA-IR) is utilized as a marker of insulin resistance18, and the homeostasis model assessment of percent beta cell function (HOMA-β) is considered to be the marker of insulin secretion. This study aimed to clarify which hippocampal subfields are vulnerable to glucose dysmetabolism. We investigated the associations between glycemic measures (HbA1c and GA) and insulin resistance (HOMA-IR) and secretion (HOMA-β) measures with hippocampal and subfield volumes in an older Japanese population with normal cognition. By targeting only cognitively normal individuals, we were able to exclude some individuals with moderate or greater AD pathology, and further clarify the association between glycemic measures or insulin resistance/ secretion and hippocampus.

Results

Characteristics of participants

The baseline survey was conducted from 2016 to 2018. A total of 11,957 community residents in 8 research sites consented to participate in the study, of which 11,410 individuals were aged 65 years or older. Full community surveys were conducted at 6 rural sites; at each of these sites, all residents aged 65 years or older were recruited based on the basic resident registers at the initial year of the baseline survey and were encouraged to participate in the surveys. As a consequence, 8030 individuals aged 65 years or older (participation rate, 67% of the total residents of this age group across the 6 sites) consented to participate in these surveys: Yahaba Town (n = 962), Nakajima Town (n = 2128), Ama Town (n = 722), Nakayama Town (n = 927), Hisayama Town (n = 1714), and Arao City (n = 1577). The remaining 3380 individuals were selected by a simple random sampling (Arakawa Ward, n = 1099) and a voluntary response sampling (Hirosaki City, n = 2281) at the 2 sites with larger populations. The recruited residents visited the research facilities (e.g., the health centers, clinics, or hospitals) for the baseline survey, MRI scans, and blood samplings. We enrolled 7400 participants with normal cognitive function (3030 men and 4370 women) in this study. Among them, 210 and 289 individuals without available measurements of HbA1c and GA, respectively, were excluded. Therefore, we analyzed 7,190 and 7,111 individuals for HbA1c and GA, respectively (Fig. 1).Fig. 1 A flow chart of enrolled individuals for each analysis of the associations between the hippocampus volumes and each diabetes status, HbA1c levels, GA levels, HOMA-IR, and HOMA-β.

GA glycated albumin, HbA1c hemoglobin A1c, HOMA-β homeostasis model assessment of percent β-cell function, HOMA-IR homeostasis model assessment for insulin resistance, JPSC-AD the Japan Prospective Studies Collaboration for Aging and Dementia, MRI magnetic resonance imaging, T1WI T1-weighted imaging.

Additionally, 3492 individuals in the sites where blood is not measured on fasting state, 747 individuals without available measurement of fasting glucose, 64 individuals with a fasting glucose level ≥7.8 mmol/L in the analysis of the HOMA-IR and the analysis of the HOMA-β were excluded. The remaining 3097 individuals were enrolled for HOMA-IR and HOMA-β levels, respectively (Fig. 1). The median values of HbA1c, GA, HOMA-IR, and HOMA-β in the study population were 5.7% [interquartile range (IQR): 5.5–6.0%], 14.8% (IQR: 13.9–16.0%), 1.08% (IQR:0.78–1.58%), and 67.0% (IQR: 47.7–93.6%), respectively. The clinical characteristics are summarized according to the levels of HbA1c, GA, HOMA-β, and HOMA-IR (Table 1 and supplementary Table 1). Table 1 shows the clinical characteristics of the participants according to HbA1c, GA and HOMA-β levels. The frequencies of hypertension, smoking habits, the mean values of age and BMI all increased significantly with higher HbA1c levels. Conversely, the frequencies of female sex, APOE ε4, the mean values of serum LDL cholesterol, and serum HDL cholesterol all decreased significantly with higher HbA1c levels. Similar findings were obtained for GA, except for the presence of APOE ε4, BMI, educational levels, and smoking habits. For HOMA-β, similar findings were obtained except for age, the presence of APOE ε4, hypertension, BMI, and drinking habits (Table 1). Similar findings were obtained for GA, except for the presence of APOE ε4, BMI, educational levels, and smoking habits. For HOMA-β, except for age, the presence of APOE ε4, hypertension, BMI, drinking habits, and estimated total intracranial volume (eTIV) (Table 1). Similar findings were obtained for serum HOMA-IR, except for age, sex, presence of APOE ε4, smoking habits, regular exercise, and eTIV (Supplementary Table 1). We also show the clinical characteristics of 7400 participants according to the status of each risk factor as supplementary Table 2.Table 1 Clinical characteristics according to hemoglobinA1c, serum glycated albumin, and homeostasis model assessment of β cell function (HOMA-β) levels

Variables	Hemoglobin A1c levels (%)	Serum glycated albumin levels (%)	HOMA-β levels	
<5.7	5.7–6.4	≥6.5	<13.9	13.9–14.8	14.9–16.0	≥16.1	≤30	>30	
Number of participants	3406	2989	795	1736	1854	1815	1706	257	2840	
Age, y	72.0 (5.7)	72.2 (5.6)	72.4 (5.4)*	70.6 (4.8)	71.5 (5.1)	72.7 (5.7)	73.7 (6.2)*	71.3 (4.9)	71.1 (5.1)	
Women, %	60.1	61.1	48.0*	54.7	62.7	64.2	54.5*	31.9*	62.3	
ApoE Ɛ4, present, %	18.1	16.5	15.0*	16.1	17.8	17.6	16.7	19.8	17.6	
Hypertension, %	48.6	56.6	64.8*	52.1	49.5	51.7	61.6*	70.3	69.6	
BMI, kg/m2	23.3 (3.3)	23.7 (3.3)	24.6 (3.5)*	24.1 (3.2)	23.3 (3.1)	22.8 (3.2)	23.1 (3.4)*	21.6 (2.6)*	23.1 (3.1)	
Serum LDL-chol, mg/dL	118.7 (30.3)	118.7 (30.3)	113.3 (30.6)*	121.1 (31.6)	120.3 (29.5)	117.9 (29.4)	113.1 (29.8)*	113.8 (31.5)*	123.1 (30.6)	
Serum HDL-chol, mg/dL	65.4 (16.9)	61.9 (16.5)	56.2 (15.3)*	60.6 (15.8)	64.0 (16.9)	65.0 (17.2)	62.3 (17.6)*	70.0 (18.3)*	64.4 (16.7)	
Education ≤ 9 y, %	25.1	25.1	25.1	22.1	23.9	23.9	27.7*	23.3	20.4	
Current smoking habits, %	8.5	7.8	9.8*	11.8	7.4	6.9	7.3*	15.2*	7.0	
Current alcohol intakes, %	47.5	41.1	43.2	52.9	43.9	40.7	40	62.3*	44.5	
Regular exercise, %	43.9	44.2	43.5	42.9	44.9	42.7	45.6	48.6	44.0	
Estimated intracranial volume, ×103 mm3	1421.3 (155.8)	1409.6 (150.7)	1433.1 (156.1)	1423.8 (155.2)	1410.4 (153.8)	1408.0 (150.5)	1430.3 (155.0)	1449.6* (140.8)	1375.6 (146.7)	
APOE apolipoprotein E, BMI body mass index, eTIV estimated intracranial volume, HDL-chol high-density lipoprotein cholesterol, HOMA-β homeostasis model assessment of beta cell function, LDL chol low-density lipoprotein cholesterol. Values were shown as mean values (standard deviations or frequencies). *p for trend < 0.05.

Associations of hippocampal and subfield volumes with diabetic status

We analyzed the hippocampal volume (HV) and volume of 12 hippocampal subfields [hippocampus amygdala transition area (HATA), fimbria, hippocampal fissure, molecular layer, granule cell and molecular cell layer of the dentate gyrus (GC ML DG), Cornu Ammonis (CA) 1, CA3, CA4, subiculum, presubiculum, parasubiculum, and hippocampal tail] (Fig. 2A). When we checked the normality, the distributions of outcome variables such as HV and the volume of 12 hippocampus subfields were found to be normal. Figure 3A–C show the whole hippocampus with a significantly lower volume in the higher levels of HbA1c or GA, or the lower levels of HOMA-β in the Models 1 and 2 analysis (Fig. 3A–C). Figure 2B–D show the hippocampal subfields with significantly lower volumes in the higher levels of HbA1c or GA, or the lower levels of HOMA-β in the Model 2 analysis (Fig. 2B–D). Regarding the levels of HbA1c, substantial differences were observed in the whole hippocampus and following subfields: fimbria, hippocampal fissure, subiculum, presubiculum, and hippocampal tail after adjusting for age, sex, research site, educational levels, and eTIV (Model 1), and fimbria, subiculum, presubiculum, and hippocampal tail after adjusting for age, sex, research site, educational levels, eTIV, presence of APOE ε4, hypertension, BMI levels, serum LDL and HDL cholesterol levels, regular exercise and smoking and drinking habits (Model 2) (Table 2, Fig. 2B). Higher HbA1c levels showed smaller hippocampal subfield volume (HSV) in the fimbria subiculum, presubiculum, and hippocampal tail (Table 2, Fig. 2B). No subfields showed significant differences in the non-DM participants (Supplementary Table 3).Fig. 2 Hippocampal subfields and the relationships between hippocampal subfields and glycemic measures or insulin secretion.

A A schematic representation of the right hippocampus in a coronal section. Hippocampal subfields are represented in different colors. HATA Hippocampus-amygdala-transition-area, GC, DG, ML, Granule cell and molecular cell layer of the dentate gyrus, CA Cornu Ammonis. Notice that the subfield HATA is transposed from an anterior coronal section, while the tail is transposed from a posterior coronal section. B–D A schematic representation displaying the substantial associations between hippocampal subregions and glycemic measures or insulin secretion measures in the analysis of the multivariable-adjusted values (Model 2): HbA1c (B), GA (C), and HOMA-β value (D). Gray color represents a substantially smaller volume in the subfields.

Fig. 3 The mean values of the volumes of the whole hippocampus according to HbA1c, GA, and HOMA-β value.

A–C The mean values of the volumes of the whole hippocampus according to HbA1c (A), GA (B), and HOMA-β value (C), with analysis of the age-, sex-, research site-, and educational levels-, estimated intracranial volume (eTIV)- adjusted values (Model 1) and multivariable-adjusted values (Model 2). †<0.05. ‡<0.001.

Table 2 Multivariable-adjusted mean values of the volumes of the hippocampus and hippocampal subregions according to hemoglobinA1c levels

	Hemoglobin A1c levels, %	p for trend	q value of FDR correction	
<5.7 (n = 3406)	5.7–6.4 (n = 2989)	≥6.5 (n = 795)	
Whole hippocampus, HV, mm3	6187.727 (6144.512–6230.942)	6193.960 (6149.737–6238.183)	6122.181 (6067.664–6176.698)	0.003*	–	
Hippocampal subregions	
 HATA, HV, mm3	97.152 (95.889–98.416)	96.858 (95.565–98.152)	95.597 (94.003–97.191)	0.046*	0.069	
 Fimbria, HV, mm3	102.353 (99.642–105.064)	99.652 (96.878–102.427)	93.592 (90.172–97.012)	<0.001*	<0.001†	
 Hippocampal fissure, HV, mm3	346.103 (342.022–350.184)	348.721 (344.545–352.898)	350.870 (345.721–356.019)	0.025*	0.060	
 Molecular_layer, HV, mm3	803.394 (796.486–810.303)	805.025 (797.955–812.094)	796.674 (787.959–805.389)	0.049*	0.065	
 GC ML DG, HV, mm3	540.797 (536.343–545.251)	540.954 (536.396–545.511)	535.250 (529.632–540.869)	0.026*	0.052	
 CA1, HV, mm3	1211.672 (1201.436–1221.908)	1213.804 (1203.328–1224.279)	1203.977 (1191.063–1216.890)	0.150	0.180	
 CA3, HV, mm3	397.392 (393.178–401.607)	399.835 (395.523–404.148)	395.177 (389.860–400.494)	0.038*	0.065	
 CA4, HV, mm3	478.310 (474.420–482.201)	479.303 (475.322–483.284)	475.788 (470.880–480.696)	0.180	0.196	
 Subiculum, HV, mm3	838.303 (831.211–845.395)	836.156 (828.898–843.413)	824.620 (815.673–833.567)	<0.001*	0.002†	
 Presubiculum, HV, mm3	560.557 (554.904–566.210)	557.340 (551.555–563.125)	550.431 (543.300–557.562)	0.001*	0.004†	
 Parasubiculum, HV, mm3	109.487 (107.416–111.557)	108.293 (106.174–110.412)	108.706 (106.094–111.318)	0.180	0.196	
 Hippocampal tail, HV, mm3	1048.310 (1037.476–1059.144)	1056.740 (1045.653–1067.827)	1042.368 (1028.701–1056.036)	0.006*	0.018†	
CA Cornu Ammonis, eTIV estimated intracranial volume, FDR false discovery rate, GC ML DG granule cell and molecular cell layer of the dentate gyrus, HATA hippocampus amygdala transition area, HV hippocampal volume. Values are shown as multivariable-adjusted mean values (95% confidence intervals) where values are calculated as follows: (left + right) volumes of hippocampus or hippocampal subregions. Adjusted for age, sex, educational level, research site, apolipoprotein E Ɛ4, body mass index, hypertension, serum low-density lipoprotein cholesterol, serum high-density lipoprotein cholesterol, current smoking habits, current alcohol intakes, regular exercise, eTIV. *p for trend <0.05. †q value of FDR correction <0.05.

Significant associations were observed between the GA levels and HV and HSV. Substantial differences were found in the whole hippocampus and the following subfields: HATA, fimbria, hippocampal fissure, GC ML DG, CA4, subiculum, and presubiculum in Model 1, and fimbria, hippocampal fissure, GC ML DG, CA4, subiculum, and presubiculum in Model 2 (Table 3, Figs. 2C and 3B). The group with higher GA levels showed smaller HSV in the fimbria, GC ML DG, CA4, subiculum, and presubiculum, and larger HSV in the hippocampal fissure. A significant difference was found only in the fimbria in the analysis of the non-DM participants (Supplementary Table 4).Table 3 Multivariable-adjusted mean values of the volumes of the hippocampus and hippocampal subregions according to serum glycated albumin levels

	Serum glycated albumin levels, %	p for trend	q value of FDR correction	
<13.9 (n = 1736)	13.9–14.8 (n = 1854)	14.9–16.0 (n = 1815)	≥16.1 (n = 1706)	
Whole hippocampus, HV, mm3	6186.512 (6139.262−6233.762)	6186.906 (6139.777−6234.035)	6201.668 (6154.382−6248.945)	6137.553 (6090.263−6184.843)	0.003*	−	
Hippocampal subregions	
 HATA, HV, mm3	97.551 (96.134−98.967)	97.781 (96.396−99.193)	98.047 (96.631−99.463)	96.525 (95.109−97.942)	0.031*	0.053	
 Fimbria, HV, mm3	103.165 (100.207−106.122)	102.379 (99.429−105.330)	101.703 (98.743−104.663)	94.823 (91.863−97.783)	<0.001*	<0.001†	
 Hippocampal fissure, HV, mm3	344.556 (340.118−348.994)	344.140 (339.714−348.567)	347.012 (342.570−351.453)	349.329 (344.888−353.771)	0.009*	0.027†	
 Molecular_layer, HV, mm3	805.593 (798.038−813.147)	805.133 (797.598−812.668)	802.392 (794.832−809.952)	798.359 (790.799−805.920)	0.059	0.078	
 GC ML DG, HV, mm3	541.073 (536.208−545.938)	540.880 (536.027−545.733)	542.606 (537.737−547.475)	534.958 (530.088−539.827)	<0.001*	0.001†	
 CA1, HV, mm3	1212.591 (1201.390−1223.792)	1209.935 (1198.763−1221.108)	1214.922 (1203.712−1226.131)	1204.180 (1192.969−1215.390)	0.075	0.112	
 CA3, HV, mm3	396.994 (392.388−401.600)	398.176 (393.581−402.770)	399.892 (395.282−404.502)	395.893 (391.283−400.503)	0.125	0.136	
 CA4, HV, mm3	478.029 (473.777−482.281)	478.330 (474.089−482.571)	480.370 (476.115−484.625)	475.274 (471.019−479.530)	0.019*	0.038†	
 Subiculum, HV, mm3	838.538 (830.778−846.299)	836.945 (829.205−844.686)	838.422 (830.656−846.188)	828.178 (820.411−835.945)	0.001*	0.004†	
 Presubiculum, HV, mm3	560.138 (553.959−564.161)	557.998 (551.835−564.161)	559.778 (553.595−565.961)	552.829 (546.645−559.013)	0.009*	0.027†	
 Parasubiculum, HV, mm3	109.262 (107.003−111.521)	108.682 (106.429−110.935)	108.994 (106.734−111.255)	108.092 (105.831−110.353)	0.585	0.585	
 Hippocampal tail, HV, mm3	1043.944 (1032.095−1055.793)	1051.311 (1039.492−1063.129)	1055.309 (1043.450−1067.167)	1049.210 (1037.350−1061.069)	0.092	0.110	
CA Cornu Ammonis, eTIV estimated intracranial volume, FDR false discovery rate, GC ML DG granule cell and molecular cell layer of the dentate gyrus, HATA hippocampus amygdala transition area, HV hippocampal volume. Values are shown as multivariable-adjusted mean values (95% confidence intervals), where values are calculated as follows: (left + right) volumes of hippocampus or hippocampal subregions. Adjusted for age, sex, educational level, research site, apolipoprotein E Ɛ4, body mass index, hypertension, serum low-density lipoprotein cholesterol, serum high-density lipoprotein cholesterol, current smoking habits, current alcohol intakes, regular exercise, eTIV. * p for trend <0.05. †q value of FDR correction <0.05.

There were substantial associations between HOMA-β levels and the HV and HSV. Significant differences were found in the whole hippocampus and the fimbria in both Model 1 and Model 2 (Table 4, Figs. 2D and 3C). The HV and HSV in these areas were smaller in the group with a lower HOMA-β. In the analysis of participants without DM, substantial differences were found in the whole hippocampus and the fimbria (Supplementary Table 5).Table 4 Multivariable-adjusted mean values of the volumes of the hippocampus and hippocampal subregions according to homeostasis model assessment of β cell function (HOMA-β) levels

	HOMA-β levels	p value	q value of FDR correction	
≤30 (n = 257)	>30 (n = 2840)	
Whole hippocampus, HV, mm3	6121.331 (6024.162–6218.500)	6208.870 (6132.305–6285.434)	0.013*	–	
Hippocampal subregions	
 HATA, HV, mm3	93.744 (90.970–96.518)	95.459 (93.273–97.645)	0.087	0.130	
 Fimbria, HV, mm3	101.041 (94.801–107.281)	108.221 (103.304–113.138)	0.001*	0.012†	
 Hippocampal fissure, HV, mm3	341.212 (0332.141–350.284)	337.296 (330.148–344.444)	0.232	0.253	
 Molecular_layer, HV, mm3	870.085 (854.298–885.872)	880.248 (867.808–892.687)	0.075	0.150	
 GC ML DG, HV, mm3	526.831 (517.148–536.515)	535.342 (527.712–542.972)	0.015*	0.09	
 CA1, HV, mm3	1183.722 (1160.750–1206.694)	1198.105 (1180.004–1216.205)	0.083	0.142	
 CA3, HV, mm3	390.998 (381.655–400.342)	395.505 (388.142–402.867)	0.182	0.242	
 CA4, HV, mm3	465.290 (456.866–473.713)	471.411 (464.773–478.048)	0.044*	0.132	
 Subiculum, HV, mm3	813.709 (798.120–829.297)	825.507 (813.224–837.790)	0.036*	0.144	
 Presubiculum, HV, mm3	540.658 (528.446–552.870)	545.982 (536.360–555.605)	0.227	0.272	
 Parasubiculum, HV, mm3	109.341 (104.803–113.879)	109.044 (105.469–112.620)	0.856	0.856	
 Hippocampal tail, HV, mm3	1025.912 (1001.013–1050.811)	1044.046 (1024.427–1063.665)	0.044*	0.132	
CA Cornu Ammonis, eTIV estimated intracranial volume, FDR false discovery rate, GC ML DG granule cell and molecular cell layer of the dentate gyrus, HATA hippocampus amygdala transition area, HOMA-β homeostasis model assessment of beta cell function, HV hippocampal volume. Values are shown as multivariable-adjusted mean values (95% confidence intervals), where values are calculated as follows: (left + right) volumes of hippocampus or hippocampal subregions. Adjusted for age, sex, educational level, research site, apolipoprotein E Ɛ4, body mass index, hypertension, serum low-density lipoprotein cholesterol, serum high-density lipoprotein cholesterol, current smoking habits, current alcohol intakes, regular exercise, eTIV. *p for trend <0.05. †q value of FDR correction <0.05.

We did not find any significant associations between the HOMA-IR level and either the HV or HSV (Supplementary Table 6). Analyses of non-DM participants showed similar results (Supplementary Table 7).

The results of multiple linear-regressions analysis for sensitivity analysis, showed that HbA1c and GA were similar to the original analysis, and log-transformed HOMA-β was significantly related to fimbria, GC ML DG, and CA1, and FDR correction also showed an association with fimbria (supplementary Tables 8–11).

Regarding the stratified analysis by age, only the group under 75 years of age showed significant differences and the p value for the interaction effect was less than 0.05 in fimbria and hippocampal fissure for GA (Supplementary Tables 12–15). About the results of stratified analysis by presence/absence of ApoE Ɛ4, the group without ApoE Ɛ4 showed significant differences and the p value for the interaction effect was <0.05 in fimbria for HbA1c and hippocampal tail for HOMA-β (Supplementary Tables 16–19).

When we analyzed including people with dementia or MCI, we observed substantially the same results except for the number of subfields of hippocampus showing significant association increased from 4 to 5 for HbA1c and 6 to 11 for GA and disappeared the differences of HV for HOMA-β (Supplementary Tables 20–23).

Discussion

This cross-sectional study showed substantial associations between a higher blood hyperglycemic state or lower insulin secretion and extensive smaller hippocampal volume in some subregions. Particularly, it was found that higher levels of HbA1c caused a smaller volume of the hippocampal tail, fimbria, subiculum, and presubiculum, that higher levels of GA caused a smaller volume of fimbria, dentate gyrus (GC ML DG), CA4, subiculum, presubiculum, and that lower levels of the HOMA-β caused the smaller volume of fimbria. In particular, the higher levels of GA, the more subfields had smaller volumes.

The significant interaction effects between GA and age were observed in fimbria, and hippocampal fissure. We considered that this result reflected more AD pathology, vascular disease, florid changes, and other pathologies added in older participants, and the relationships between diabetes markers and hippocampal subregion volume changes with age. The mechanism of the interaction effect between HbA1c or HOMA-β and the presence/absence of ApoE Ɛ4 in the fimbria and hippocampal tail of the group without ApoE Ɛ4 is not known.

For HOMA-β, when we added people with cognitively impaired, the significant differences of HV were disappeared. We speculate that it was because people with cognitively impaired had different reasons that associated for hippocampal atrophy other than decreased insulin secretions.

The hippocampal subfields are primarily composed of the ammon horn (CA1-4), dentate gyrus that includes the molecular layer and granule cells of the molecular layer, subiculum, presubiculum, and parasubiculum. Additionally, the hippocampus includes the fimbria and HATA. The hippocampus sends major outputs from the CA1 and subiculum to the cortical regions. The CA1 and subiculum are considered the most important regions for the formation of memories such as episodic memory, spatial memory, and autonoetic consciousness19–23. Another output from the hippocampus is sent through the fimbria, which is composed of myelinated axons and comprises the Papez circuit and polysynaptic pathway. Fimbria is important for memory and learning24,25. The hippocampus receives major inputs through the dentate gyrus. The dentate gyrus is thought to contribute to the formation of novelty detection, pattern separation, pattern completion, spatial working memory, information encoding, and memory consolidation and retention26–28. The fact that higher HbA1c or GA or lower HOMA-β impairs these areas might be related to the various cognitive dysfunctions, including episodic memory, spatial memory, and learning in patients with DM. However, the present study did not assess detailed cognitive functions such as episodic memory, spatial memory, and learning, therefore the mediation of the association between the hippocampal subfields where showed lower volume in the present results and cognitive function, could not be established.

Regarding the hyperglycemia index, this study demonstrated more widespread smaller hippocampal volume, particularly with elevated GA, than with HbA1c. HbA1c reflects the mean glucose level over the preceding 3 months29, and GA has been reported to reflect the state of glucose level over the preceding 2-3 weeks30. A disadvantage of HbA1c is that HbA1c levels fluctuates with anemia31, and more than 10% of community-dwelling adults aged 65 years and older have been reported to have WHO-defined anemia32. Therefore, it is possible that HbA1c may have been less effective in indicating blood glucose levels compared to GA. Furthermore, GA has been reported to reflect short-term average glucose and fluctuations in glucose33. Past studies have reported that smaller hippocampal volume might be preceded by not only chronic hyperglycemia but also glycemic variability11, and this result is consistent with that of a previous study. Possible mechanisms underlying the association between hyperglycemia or glycemic variability and smaller hippocampal volume is known to cause oxidative stress, inflammation, and vascular damage. Hyperglycemia is believed to promote the production of advanced glycation end products (AGEs), and the blood receptor of AGEs (i.e., RAGE levels) is altered in patients with prediabetes associated with higher oxidative stress levels13,14. In animal studies, prediabetes rat models with cognitive decline showed neuroinflammation and neuronal apoptosis in the hippocampus34. Glucose toxicity causes microvascular ischemic damage, and chronic hypoxia causes microglia activation, phosphorylation of tau, and cell death, all of which could lead to smaller volume of the hippocampus11.

This study showed that the low insulin secretory capacity results in smaller volume of the whole hippocampus and numerous hippocampal subregions. Furthermore, this study showed that even in people without DM, reduced levels of HOMA-β were associated with smaller volume of the whole hippocampus and fimbria, which are important for memory. The possible mechanisms of smaller hippocampal volume induced by decreased insulin levels are decreased neurogenesis and excessive production of amyloid-β (Aβ), and phosphorylation of tau2,12. Insulin and its receptors are widely expressed in the brain and play important roles in neuronal proliferation and differentiation2. The subgranular zone, which is located in the dentate gyrus in the hippocampus, is one of the two major neural stem cell regions of adults, and insulin and insulin-like growth factors are crucial in neurogenesis and neural stem cell self-renewal through different ligand-receptor interactions2. Furthermore, insulin has previously been reported to promote dendritic spines formation in rat hippocampal neurons35. Therefore, decreased insulin might weaken neurogenesis and decrease volumes of hippocampus or hippocampal subfields. Another possible mechanism is Aβ overproduction and hyperphosphorylation of the tau protein11. Insulin has been reported to be involved in the regulation of Aβ fibrillization, and to protect neurons against Aβ-induced cell-death36, and Aβ overproduction has been reported in the brain of mice that were administered streptozotocin37,38. Furthermore, the deficiency in insulin signaling promotes the tau phosphorylation mediated by glycogen synthase kinase 3β, which is one of the tau phosphorylases39.

In this study, no substantial association was observed between HOMA-IR values and hippocampal volume. Insulin resistance was hypothesized to reduce the insulin concentration in the cerebrospinal fluid40, and result in Aβ overproduction and excessive amount of hyperphosphorylated tau protein41. Some studies reported that HOMA-IR levels were significantly associated with smaller volume of hippocampus and its subfields in non-elderly patients with type 2 DM and postmenopausal women undergoing hormone therapy2,42. Further large-scaled studies are required to clarify the association between HOMA-IR levels and atrophies of hippocampus and its subregions in community-dwelling elderly.

This study had several limitations. First, we did not obtain data on the duration of DM. Second, this study did not exclude patients with preclinical AD because amyloid PET and/or cerebrospinal fluid tests were not performed. Thus, smaller hippocampal volume may also be associated with AD pathogenesis. Third, because the findings of this study were derived from cross-sectional data, the temporal trends of glycemic measures, insulin secretion and atrophy of the hippocampus and its subfields were unknown. Fourth, some study areas used 1.5 T MRIs, and others used 3 T MRIs. Although we standardized MRI images, and we tried to adjust for errors in advance by including the survey sites as an adjustment variable, the MRI conditions might not be exactly the same. Finally, the data in this study are for the Japanese only; therefore, generalizability to other ethnicities, and races has not been examined. The strengths of this study are that it was a large study that could adjust for many factors. In conclusion, this study revealed that higher plasma HbA1c levels, higher serum GA levels, and lower HOMA-β levels were related to smaller hippocampal volume including multiple subfields. Particularly higher serum GA levels or low levels of HOMA-β can be associated with smaller hippocampal volume even in patients with non-DM. Our findings indicate that sufficient glucose control or primary prevention of diabetes is important for the prevention of dementia, and that postprandial hyperglycemia, postprandial glucose fluctuations, and low insulin secretion have a more specific effect on the development of smaller hippocampal volume. Further basic research and prospective longitudinal studies are required to verify these findings.

Methods

Study population

Among the 11,410 participants in the JPSC-AD study aged 65 years or older, 9646 underwent MRI scans with 3-dimensional T1-weighted images. After excluding 167 participants who did not pass the quality control of the FreeSurfer analysis, 103 participants who did not have hippocampal measurement data, and 1976 participants who were diagnosed with dementia or mild cognitive impairment, 7400 participants with normal cognitive function (3030 men and 4370 women) were enrolled in this study (Fig. 1).

Standard protocol approvals, registrations, and patient consents

The study was approved by the Kyushu University Institutional Review Board for clinical research (approval number 686-10) and by each of the local ethics committee of the eight research institutes: Kanazawa University (approval number 2185), Hirosaki University (approval number 2019-064-3), Iwate Medical University (approval number HG2020-017), Keio University School of Medicine (approval number 20160214), Matsue Medical Center (approval number H28-14), and Ehime University (approval number 1610004 and 2210016), Kumamoto University (approval number 333), and Tohoku University (approval number 2021-1-245). The all participants gave their informed consent.

MRI analysis

Structural MRI studies were performed using 1.5 T MRI (four Philips, one Hitachi, and one General-Electric [GE]) and 3 T MRI (one GE and one Siemens) machines. The two sites, Arakawa Ward and Hirosaki City used 3 T MRI, and the other sites used 1.5 T MRI. 3D volumetric acquisition of T1-weighted turbo field echo images was conducted according to the brain MRI protocol for the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study43. In addition, the brain MRI data were standardized by using the MRI Phantom, Human Phantom, and ADNI Phantom to correct geometric distortions among the different pieces of equipment. All T1-structural images were analyzed using FreeSurfer version 7.0 (FreeSurfer version 7.0; http://surfer.nmr.mgh.harvard.edu)44 in Tohoku University and preprocessed according to the standard method. The volumes of the area of interest were created using FreeSurfer 7.045, in particular, the HV and volume of 12 HSV (Fig. 2A) and eTIV were calculated automatically. The hippocampal and subfield volumes were calculated as the sum of the right and left volumes, respectively.

Measurements of HbA1c, GA, HOMA-IR, and HOMA-β and diagnosis of DM

Plasma HbA1c levels were measured using the National Glycohemoglobin Standardization Program (NGSP), and serum GA levels were determined using the enzymatic method. Additionally, serum insulin levels were measured using a chemiluminescence immunoassay. Detailed measurement methods of blood chemistry have been previously reported15. For analyses of the association between the HbA1c category and hippocampal volumes, we categorized HbA1c using standard clinical cutoff points: normal, ≤5.7%; prediabetes, 5.7–6.5%; and diabetes, ≤6.5%. For the analyses, the GA value was divided into quartiles. We calculated the HOMA-IR using the following formula: HOMA-IR = fasting serum insulin (μU/mL)/fasting plasma glucose (mmol/L)/22.546. Subsequently, we calculated the HOMA-β using the following equation: HOMA-β = fasting serum insulin (μU/mL) × 20/[fasting plasma glucose (mmol/L)–3.5]46. For analyses, the HOMA-IR was categorized using standard clinical cutoff points: ≤1.6%, 1.6–2.5%, ≥2.5%, and HOMA-β was also categorized using standard clinical cutoff points: ≤30%, and >30%. For the HOMA-IR and HOMA-β analysis, we excluded individuals who administered insulin injections to remove the effects of exogenous insulin46. DM was determined by the 2010 American Diabetes Association (ADA) criteria47.

Other risk factor and confounding factors measurements

We identified gender, ApoE Ɛ4 status, alcohol consumption, low education, and exercise habits as confounding factors associated with reduced hippocampal volume. Furthermore, hypertension, obesity, hyper-LDL-cholesterolemia, hypo-HDL-cholesterolemia, and smoking, identified as risk factors for vascular disease that could serve as modifiers. Each participant completed a self-administered questionnaire containing questions on sociodemographic data (age, sex, and educational level), medical history (hypertension), regular exercise, and smoking and drinking habits. Regular exercise was defined as physical activity specifically undertaken for exercise or sports performed for at least 30 min twice per week over the most recent year or longer. Completed questionnaires were reviewed by trained researchers to identify unanswered or inconsistent items. The body mass index (BMI) (kg/m2) was used as an indicator of obesity. Serum HDL and LDL cholesterol were enzymatically measured15. To determine Apolipoprotein E (APOE) polymorphisms, two single nucleotide polymorphisms (rs429358 and rs7412) were genotyped using a multiplex PCR-based targeted sequencing method, as previously reported48.

Statistical analyses

Clinical characteristics were evaluated using the t-test or Jonckheere-Tsrpsta test and chi-squared test or Mantel-Haenszel test for continuous and categorical variables, respectively. Analysis of covariance was used to estimate and compare multivariable-adjusted values and their 95% confidence intervals for HV and each HSV. Model 1 was adjusted for age, sex, research site, educational levels and eTIV. Model 2 was further adjusted for the presence of APOE ε4 allele, hypertension, BMI levels, serum LDL and HDL cholesterol levels, regular exercise, and smoking and drinking habits. We performed additional analyses on participants without DM. The problem of multiple comparisons was addressed by controlling Benjamini–Hochberg false discovery rate (FDR)49. The FDR-adjusted p-values (i.e., q values) below 0.05 were considered statistically significant. SPSS software package (version 29; SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. For sensitivity analysis, multiple linear-regressions analysis was performed using the HV and each HSV and the real values of HbA1c, GA. Since HOMA-IR and HOMA-β were not normally distributed, a log transformation was performed to confirm that they were normally distributed, and the log-transformed HOMA-IR and HOMA-β values were used. The covariates were which of the above model 2 covariates.

Furthermore, to confirm the interaction between the diabetes markers and other risk factors for hippocampal atrophy, a stratified analysis of age and the presence of ApoE Ɛ4 as a representative was also performed and confirmed the interaction effect. The stratified analysis about age was analyzed separately for those under 75 and over 75 years of age.

We also performed a sensitivity analysis that included individuals with dementia and MCI.

Supplementary information

Supplementary Table

Supplementary information

The online version contains supplementary material available at 10.1038/s41514-024-00164-2.

Acknowledgements

We would like to thank the participants for contributing their time to the JPSC-AD study and gratefully acknowledge the diligent work and contributions of all researchers and investigators in the JPSC-AD Study Group. This study was supported by the Japan Agency for Medical Research and Development (JP23dk0207053) and Suntory Holdings Limited (Osaka, Japan). The funders had no role in the design of the study, the collection, analysis, and interpretation of data, or the writing of the manuscript.

Author contributions

Research idea and study design: A.S., M.N.-S., T.N., K.O.; data acquisition: A.S., M.N.-S., S.S., Y.U., Y.T., B.T., J.H., T.O., T.H., Y.T., S.N,. T.M., M.M., K.N,. J.I, M.T.; data analysis/interpretation and supervision or mentorship: M.N.-S., H.N., T.N., K.O.; statistical analysis: A.S., M.N.-S. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Data availability

The datasets used in the present study are not publicly available, because they contain confidential clinical data on the study participants. However, the data are available upon reasonable request and with the permission of the Principal Investigator of this study, Toshiharu Ninomiya.

Code availability

No custom code or mathematical algorithm was developed for this study. Details regarding the specific codes used can be found in the references cited. As indicated in the references, any access restrictions or licensing information associated with the codes used can be obtained from the respective sources.

Competing interests

A.S., M.N.-S., S.S., Y.U., Y.T., B.T., J.H., T.O., T.H., Y.T., S.N., T.M., M.M., K.N., J.-i.I., M.T., H.N., and K.O. declares no competing financial or non-financial interests. T.N. declares no competing non-financial interests but the following competing financial interests: Grants from Suntory Holdings Limited.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

A list of authors and their affiliations appears at the end of the paper.
==== Refs
References

1. Zhang W Hippocampal subfields atrophy contribute more to cognitive impairment in middle-aged patients with type 2 diabetes rather than microvascular lesions Acta Diabetol. 2021 58 1023 1033 10.1007/s00592-020-01670-x 33751221
Zhang, W. et al. Hippocampal subfields atrophy contribute more to cognitive impairment in middle-aged patients with type 2 diabetes rather than microvascular lesions. Acta Diabetol. 58, 1023–1033 (2021).33751221 10.1007/s00592-020-01670-x
2. Li M Altered hippocampal subfields volumes is associated with memory function in type 2 diabetes mellitus Front. Neurol. 2021 12 756500 10.3389/fneur.2021.756500 34899576
Li, M. et al. Altered hippocampal subfields volumes is associated with memory function in type 2 diabetes mellitus. Front. Neurol. 12, 756500 (2021).34899576 10.3389/fneur.2021.756500
3. Lee S Hippocampal subregional alterations and verbal fluency in the early stage of type 2 diabetes mellitus Eur. J. Neurosci. 2021 54 7550 7559 10.1111/ejn.15505 34687097
Lee, S. et al. Hippocampal subregional alterations and verbal fluency in the early stage of type 2 diabetes mellitus. Eur. J. Neurosci. 54, 7550–7559 (2021).34687097 10.1111/ejn.15505
4. Li M Atrophy patterns of hippocampal subfields in T2DM patients with cognitive impairment Endocrine 2020 68 536 548 10.1007/s12020-020-02249-w 32172485
Li, M. et al. Atrophy patterns of hippocampal subfields in T2DM patients with cognitive impairment. Endocrine 68, 536–548 (2020).32172485 10.1007/s12020-020-02249-w
5. Sadanand S Memory and executive functions in persons with type 2 diabetes: a meta-analysis Diabetes Metab. Res. Rev. 2016 32 132 142 10.1002/dmrr.2664 25963303
Sadanand, S. et al. Memory and executive functions in persons with type 2 diabetes: a meta-analysis. Diabetes Metab. Res. Rev. 32, 132–142 (2016).25963303 10.1002/dmrr.2664
6. Palta P Magnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains J. Int. Neuropsychol. Soc. 2014 20 278 291 10.1017/S1355617713001483 24555960
Palta, P. et al. Magnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains. J. Int. Neuropsychol. Soc. 20, 278–291 (2014).24555960 10.1017/S1355617713001483
7. Ohara T Glucose tolerance status and risk of dementia in the community: the Hisayama study Neurology 2011 77 1126 1134 10.1212/WNL.0b013e31822f0435 21931106
Ohara, T. et al. Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology 77, 1126–1134 (2011).21931106 10.1212/WNL.0b013e31822f0435
8. Noguchi-Shinohara M Diabetes mellitus, elevated hemoglobin A1c, and glycated albumin are associated with the presence of all-cause dementia and Alzheimer’s disease: the JPSC-AD Study J. Alzheimers Dis. 2022 85 235 247 10.3233/JAD-215153 34806607
Noguchi-Shinohara, M. et al. Diabetes mellitus, elevated hemoglobin A1c, and glycated albumin are associated with the presence of all-cause dementia and Alzheimer’s disease: the JPSC-AD Study. J. Alzheimers Dis. 85, 235–247 (2022).34806607 10.3233/JAD-215153
9. Hu Y Resveratrol improves diabetes-induced cognitive dysfunction in part through the miR-146a-5p/TXNIP axis Kaohsiung J. Med. Sci. 2023 39 404 415 10.1002/kjm2.12643 36651333
Hu, Y. et al. Resveratrol improves diabetes-induced cognitive dysfunction in part through the miR-146a-5p/TXNIP axis. Kaohsiung J. Med. Sci. 39, 404–415 (2023).36651333 10.1002/kjm2.12643
10. Monereo-Sánchez J The association of prediabetes and type 2 diabetes with hippocampal subfields volume: the Maastricht study NeuroImage Clin. 2023 12 1908 1913
Monereo-Sánchez, J. et al. The association of prediabetes and type 2 diabetes with hippocampal subfields volume: the Maastricht study. NeuroImage Clin. 12, 1908–1913 (2023).
11. Ohara T Elevated serum glycated albumin and glycated albumin: hemoglobin A 1c ratio were associated with hippocampal atrophy in a general elderly population of Japanese: the Hirayama Study J. Diabetes Investig. 2020 11 971 979 10.1111/jdi.13220 31999889
Ohara, T. et al. Elevated serum glycated albumin and glycated albumin: hemoglobin A 1c ratio were associated with hippocampal atrophy in a general elderly population of Japanese: the Hirayama Study. J. Diabetes Investig. 11, 971–979 (2020).31999889 10.1111/jdi.13220
12. Adachi Y Ota K Minami I Yamada T Watanabe T Lower insulin secretion is associated with hippocampal and parahippocampal gyrus atrophy in elderly patients with type 2 diabetes mellitus J. Diabetes Investig. 2021 12 1908 1913 10.1111/jdi.13554 33783982
Adachi, Y., Ota, K., Minami, I., Yamada, T. & Watanabe, T. Lower insulin secretion is associated with hippocampal and parahippocampal gyrus atrophy in elderly patients with type 2 diabetes mellitus. J. Diabetes Investig. 12, 1908–1913 (2021).33783982 10.1111/jdi.13554
13. Vlassara H Palace MR Diabetes and advanced glycation endproducts J. Intern. Med. 2002 251 87 101 10.1046/j.1365-2796.2002.00932.x 11905595
Vlassara, H. & Palace, M. R. Diabetes and advanced glycation endproducts. J. Intern. Med. 251, 87–101 (2002).11905595 10.1046/j.1365-2796.2002.00932.x
14. Huang M Que Y Shen X Correlation of the plasma levels of soluble RAGE and endogenous secretory RAGE with oxidative stress in pre-diabetic patients J. Diabetes Complicat. 2015 29 422 426 10.1016/j.jdiacomp.2014.12.007
Huang, M., Que, Y. & Shen, X. Correlation of the plasma levels of soluble RAGE and endogenous secretory RAGE with oxidative stress in pre-diabetic patients. J. Diabetes Complicat. 29, 422–426 (2015).10.1016/j.jdiacomp.2014.12.007
15. Ninomiya T Study design and baseline characteristics of a population-based prospective cohort study of dementia in Japan: the Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD) Environ. Health Prev. Med. 2020 25 64 10.1186/s12199-020-00903-3 33129280
Ninomiya, T. et al. Study design and baseline characteristics of a population-based prospective cohort study of dementia in Japan: the Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD). Environ. Health Prev. Med. 25, 64 (2020).33129280 10.1186/s12199-020-00903-3
16. Kim KJ Lee BW The roles of glycated albumin as intermediate glycation index and pathogenic protein Diabetes Metab. J. 2012 36 98 107 10.4093/dmj.2012.36.2.98 22540045
Kim, K. J. & Lee, B. W. The roles of glycated albumin as intermediate glycation index and pathogenic protein. Diabetes Metab. J. 36, 98–107 (2012).22540045 10.4093/dmj.2012.36.2.98
17. Iberg N Flückiger R Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites J. Biol. Chem. 1986 261 13542 13545 10.1016/S0021-9258(18)67052-8 3759977
Iberg, N. & Flückiger, R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J. Biol. Chem. 261, 13542–13545 (1986).3759977 10.1016/S0021-9258(18)67052-8
18. Conwell LS Trost SG Brown WJ Batch JA Indexes of insulin resistance and secretion in obese children and adolescents: a validation study Diabetes Care 2004 27 314 319 10.2337/diacare.27.2.314 14747206
Conwell, L. S., Trost, S. G., Brown, W. J. & Batch, J. A. Indexes of insulin resistance and secretion in obese children and adolescents: a validation study. Diabetes Care 27, 314–319 (2004).14747206 10.2337/diacare.27.2.314
19. Jeong Y Role of the hippocampal CA1 region in incremental value learning Sci. Rep. 2018 29 9870 10.1038/s41598-018-28176-5
Jeong, Y. et al. Role of the hippocampal CA1 region in incremental value learning. Sci. Rep. 29, 9870 (2018).10.1038/s41598-018-28176-5
20. Tamura R Nakada Y Nishijo H Miyake N Ono T Ameliorative effects of tamolarizine on place learning impairment induced by transient forebrain ischemia in rats Brain Res. 2000 853 81 92 10.1016/S0006-8993(99)02247-7 10627311
Tamura, R., Nakada, Y., Nishijo, H., Miyake, N. & Ono, T. Ameliorative effects of tamolarizine on place learning impairment induced by transient forebrain ischemia in rats. Brain Res. 853, 81–92 (2000).10627311 10.1016/S0006-8993(99)02247-7
21. Bartsch T Döhring J Rohr A Jansen O Deuschl G CA1 neurons in the human hippocampus are critical for autobiographical memory, mental time travel, and autonoetic consciousness Proc. Natl. Acad. Sci. USA 2011 108 17562 17567 10.1073/pnas.1110266108 21987814
Bartsch, T., Döhring, J., Rohr, A., Jansen, O. & Deuschl, G. CA1 neurons in the human hippocampus are critical for autobiographical memory, mental time travel, and autonoetic consciousness. Proc. Natl. Acad. Sci. USA 108, 17562–17567 (2011).21987814 10.1073/pnas.1110266108
22. Matsumoto N Kitanishi T Mizuseki K The subiculum: unique hippocampal hub and more Neurosci. Res. 2019 143 1 12 10.1016/j.neures.2018.08.002 30121285
Matsumoto, N., Kitanishi, T. & Mizuseki, K. The subiculum: unique hippocampal hub and more. Neurosci. Res. 143, 1–12 (2019).30121285 10.1016/j.neures.2018.08.002
23. Morris RGM Schenk F Tweedie F Jarrard LE Ibotenate lesions of hippocampus and/or subiculum: dissociating components of allocentric spatial learning Eur. J. Neurosci. 1990 2 1016 1028 10.1111/j.1460-9568.1990.tb00014.x 12106063
Morris, R. G. M., Schenk, F., Tweedie, F. & Jarrard, L. E. Ibotenate lesions of hippocampus and/or subiculum: dissociating components of allocentric spatial learning. Eur. J. Neurosci. 2, 1016–1028 (1990).12106063 10.1111/j.1460-9568.1990.tb00014.x
24. Sutherland RJ Rodriguez AJ The role of fornix/fimbria and some related subcortical structures in place learning and memory Behav. Brain Res. 1989 32 265 277 10.1016/S0166-4328(89)80059-2 2496702
Sutherland, R. J. & Rodriguez, A. J. The role of fornix/fimbria and some related subcortical structures in place learning and memory. Behav. Brain Res. 32, 265–277 (1989).2496702 10.1016/S0166-4328(89)80059-2
25. Dahmani L Fimbria-fornix volumes is associated with spatial memory and olfactory identification in humans Front. Syst. Neurosci. 2019 13 87 10.3389/fnsys.2019.00087 32009912
Dahmani, L. et al. Fimbria-fornix volumes is associated with spatial memory and olfactory identification in humans. Front. Syst. Neurosci. 13, 87 (2019).32009912 10.3389/fnsys.2019.00087
26. Kitchigina V. F., Shubina L. V., Popova Y. The role of the dentate gyrus in mediating hippocampal functions: the healthy brain. Neurosci. Behav. Phys. 52, 1401–1417 (2022).
27. Sasaki T Dentate network activity is necessary for spatial working memory by supporting CA3 sharp-wave ripple generation and prospective firing of CA3 neurons Nat. Neurosci. 2018 21 258 269 10.1038/s41593-017-0061-5 29335604
Sasaki, T. et al. Dentate network activity is necessary for spatial working memory by supporting CA3 sharp-wave ripple generation and prospective firing of CA3 neurons. Nat. Neurosci. 21, 258–269 (2018).29335604 10.1038/s41593-017-0061-5
28. van Dijk MTV Fenton AA On how the dentate gyrus contributes to memory discrimination Neuron 2018 98 832 845 10.1016/j.neuron.2018.04.018 29731252
van Dijk, M. T. V. & Fenton, A. A. On how the dentate gyrus contributes to memory discrimination. Neuron 98, 832–845 (2018).29731252 10.1016/j.neuron.2018.04.018
29. Rohlfing CL Defining the relationship between plasma glucose and HbA (1c): analysis of glucose profiles and HbA (1c) in the Diabetes Control and Complications Trial Diabetes Care 2002 25 275 278 10.2337/diacare.25.2.275 11815495
Rohlfing, C. L. et al. Defining the relationship between plasma glucose and HbA (1c): analysis of glucose profiles and HbA (1c) in the Diabetes Control and Complications Trial. Diabetes Care 25, 275–278 (2002).11815495 10.2337/diacare.25.2.275
30. Yoshiuchi K Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes Endocr. J. 2008 55 503 507 10.1507/endocrj.K07E-089 18445997
Yoshiuchi, K. et al. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr. J. 55, 503–507 (2008).18445997 10.1507/endocrj.K07E-089
31. Katwal PC Jirjees S Htun ZM Aldawudi I Khan S The effect of anemia and the goal of optimal HbA1c control in diabetes and non-diabetes Cureus 2020 12 6
Katwal, P. C., Jirjees, S., Htun, Z. M., Aldawudi, I. & Khan, S. The effect of anemia and the goal of optimal HbA1c control in diabetes and non-diabetes. Cureus 12, 6 (2020).
32. Patel KV Epidemiology of anemia in older adults Semin. Hematol. 2008 45 210 217 10.1053/j.seminhematol.2008.06.006 18809090
Patel, K. V. Epidemiology of anemia in older adults. Semin. Hematol. 45, 210–217 (2008).18809090 10.1053/j.seminhematol.2008.06.006
33. Koga M Serum glycated albumin to haemoglobin A(1C) ratio can distinguish fulminant type 1 diabetes mellitus from type 2 diabetes mellitus Ann. Clin. Biochem. 2010 47 313 317 10.1258/acb.2010.009234 20516001
Koga, M. et al. Serum glycated albumin to haemoglobin A(1C) ratio can distinguish fulminant type 1 diabetes mellitus from type 2 diabetes mellitus. Ann. Clin. Biochem. 47, 313–317 (2010).20516001 10.1258/acb.2010.009234
34. Fakih W Dysfunctional cerebrovascular tone contributes to cognitive impairment in a non-obese rat model of prediabetic challenge: role of suppression of autophagy and modulation by anti-diabetic drugs Biochem. Pharm. 2020 178 114041 10.1016/j.bcp.2020.114041 32439335
Fakih, W. et al. Dysfunctional cerebrovascular tone contributes to cognitive impairment in a non-obese rat model of prediabetic challenge: role of suppression of autophagy and modulation by anti-diabetic drugs. Biochem. Pharm. 178, 114041 (2020).32439335 10.1016/j.bcp.2020.114041
35. Lee CC Huang CC Hsu KS Insulin promotes dendritic spine and synapse formation by the PI3K/AKT/mTOR and Rac1 signaling pathways Neuropharmacology 2011 61 867 879 10.1016/j.neuropharm.2011.06.003 21683721
Lee, C. C., Huang, C. C. & Hsu, K. S. Insulin promotes dendritic spine and synapse formation by the PI3K/AKT/mTOR and Rac1 signaling pathways. Neuropharmacology 61, 867–879 (2011).21683721 10.1016/j.neuropharm.2011.06.003
36. Rensink AAM Insulin inhibits amyloid beta-induced cell death in cultured human brain pericytes Neurobiol. Aging 2004 25 93 103 10.1016/S0197-4580(03)00039-3 14675735
Rensink, A. A. M. et al. Insulin inhibits amyloid beta-induced cell death in cultured human brain pericytes. Neurobiol. Aging 25, 93–103 (2004).14675735 10.1016/S0197-4580(03)00039-3
37. Devi L Alldred MJ Ginsberg SD Ohno M Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer’s disease PLoS One 2012 7 e32792 10.1371/journal.pone.0032792 22403710
Devi, L., Alldred, M. J., Ginsberg, S. D. & Ohno, M. Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer’s disease. PLoS One 7, e32792 (2012).22403710 10.1371/journal.pone.0032792
38. Lannert H Hoyer S Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats Behav. Neurosci. 1998 112 1199 1208 10.1037/0735-7044.112.5.1199 9829797
Lannert, H. & Hoyer, S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav. Neurosci. 112, 1199–1208 (1998).9829797 10.1037/0735-7044.112.5.1199
39. Dozza B., Smith M. A., Perry G., Tabaton M. & Strocchi P. Regulation of glycogen synthase kinase-3beta by products of lipid peroxidation in human neuroblastoma cells. J Neurochem. 89, 1224–1232 l (2004).
40. Arnold SE Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums Nat. Rev. Neurol. 2018 14 168 181 10.1038/nrneurol.2017.185 29377010
Arnold, S. E. et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat. Rev. Neurol. 14, 168–181 (2018).29377010 10.1038/nrneurol.2017.185
41. Verdile G Fuller SJ Martins RN The role of type 2 diabetes in neurodegeneration Neurobiol. Dis. 2015 84 22 38 10.1016/j.nbd.2015.04.008 25926349
Verdile, G., Fuller, S. J. & Martins, R. N. The role of type 2 diabetes in neurodegeneration. Neurobiol. Dis. 84, 22–38 (2015).25926349 10.1016/j.nbd.2015.04.008
42. Rasgon NL Insulin resistance and hippocampal volume in women at risk for Alzheimer’s disease Neurobiol. Aging 2011 32 1942 1948 10.1016/j.neurobiolaging.2009.12.005 20031276
Rasgon, N. L. et al. Insulin resistance and hippocampal volume in women at risk for Alzheimer’s disease. Neurobiol. Aging 32, 1942–1948 (2011).20031276 10.1016/j.neurobiolaging.2009.12.005
43. Jack CR The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI methods J. Magn. Reson Imaging 2008 27 685 691 10.1002/jmri.21049 18302232
Jack, C. R. et al. The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI methods. J. Magn. Reson Imaging 27, 685–691 (2008).18302232 10.1002/jmri.21049
44. Fischl B Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain Neuron 2002 33 341 355 10.1016/S0896-6273(02)00569-X 11832223
Fischl, B. et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33, 341–355 (2002).11832223 10.1016/S0896-6273(02)00569-X
45. Desikan RS An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest Neuroimage 2006 31 968 980 10.1016/j.neuroimage.2006.01.021 16530430
Desikan, R. S. et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31, 968–980 (2006).16530430 10.1016/j.neuroimage.2006.01.021
46. Matthews DR Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 1985 28 412 419 10.1007/BF00280883 3899825
Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985).3899825 10.1007/BF00280883
47. American Diabetes A. Diagnosis and classification of diabetes mellitus Diabetes Care 2010 33 S62 S69 10.2337/dc10-S062 20042775
American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care 33, S62–S69 (2010).20042775 10.2337/dc10-S062
48. Momozawa Y Low-frequency coding variants in CETP and CFB are associated with susceptibility of exudative age-related macular degeneration in the Japanese population Hum. Mol. Genet. 2016 25 5027 5034 28173125
Momozawa, Y. et al. Low-frequency coding variants in CETP and CFB are associated with susceptibility of exudative age-related macular degeneration in the Japanese population. Hum. Mol. Genet. 25, 5027–5034 (2016).28173125
49. Benjamini Y Hochberg Y Controlling the false discovery rate: a practical and powerful approach to multiple testing J. R. Stat. Soc. 1995 57 289 300 10.1111/j.2517-6161.1995.tb02031.x
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. 57, 289–300 (1995).10.1111/j.2517-6161.1995.tb02031.x
